MedTrace Logo

Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer

NCT03677414 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2018-09-19

No results posted yet for this study

Summary

In this project, we would like to focus on castration-sensitive prostate cancer (CRPC). This is a highly variable clinical picture with differentiated and burdening symptoms. The clinical parameters used to estimate the prognosis have so far only shown a very limited valence; genetic markers have so far only rarely been investigated.

In the course of our preliminary investigations, we were already able to isolate 189 plasma samples from 59 patients with metastatic prostate cancer. These samples are prepared by highly innovative techniques, e.g. "whole genome sequencing", in order to gain comprehensive insights into the spectrum of genetic changes under therapy and the associated tumor evolution. These results should be compared with the genetic material of the respective prostate tumors, which originate from previous operations. This highly comprehensive data, which will yield results on copy number changes, mutations, and gene expression, will allow analysis of signaling pathways of unprecedented resolution to increase the efficacy of targeted therapies in patients and minimize the burden of non-effective therapy side effects.

Conditions

  • Prostatic Neoplasms

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Jochen B Geigl, Prof, MD · Institute of Human Genetics

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2021-01-31
Completion
2021-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677414 on ClinicalTrials.gov